Conclusions: Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.
Increase in hematocrit is a predictable effect of testosterone therapy (1,2,3,4,5,6). Erythrocytosis is the most frequently reported adverse event in testosterone trials (2). Anecdotally, older men appear more sensitive to the erythropoietic effects of testosterone than young men (7,8,9,10)...